It is not approved for medical use anywhere yet
Patients with liver problems: The medication should also be used cautiously in patients with liver problems, necessitating regular monitoring of liver function
Important 2026 update: Compounded tirzepatide availability has significantly decreased after the FDA resolved the tirzepatide shortage
Orforglipron showed higher rates of adverse side effects such as nausea, vomiting and other gastrointestinal issues compared with semaglutide
Mean percent body weight change at 80 weeks, by dose: Retatrutide 4 mg : 19.0% (47.2 lbs) Retatrutide 9 mg : 25.9% (64.4 lbs) Retatrutide 12 mg : 28.3% (70.3 lbs) Placebo : 2.2% (5.5 lbs) Responder rates at the 12 mg dose are the more interesting number for clinicians
But in the process, it has created an ill-defined public health crisis under our noses, fed by greed and preying on vulnerable patients who turn to questionable yet convenient solutions online